|
Depression Dialogues TM — The Final Challenge
Continuing Medical Education Information
Financial Disclosure:
It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by each of the faculty members. The faculty reported the following: Dr. Adam Ashton MD has received grants/research support from Forest, GlaxoSmithKline and Solvay. Dr. Ashton MD also serves as a consultant to Eli Lilly, Forest, GlaxoSmithKline, and Pfizer and serves on the speakers bureaus of Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Organon, Pfizer, Solvay, and Wyeth-Ayerst.
Activity Objectives:
- Recognize that the majority of patients with
depression will ultimately relapse
- Outline patient counseling strategies for
initiating long-term treatment
- Explain treatment considerations in switching
and augmenting therapy in managing treatment resistant depression
- Illustrate the importance of addressing comorbid
conditions — medical and emotional — when initiating a successful
treatment plan
- Distinguish the impact of side effects on
treatment outcome in terms of quality of life and patient compliance
- Review relevant studies discussing the rationale for therapeutic options in refractory patients
Credit Designation:
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Medical Education Resources designates this educational activity for a maximum of 2.0 hours of category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity was planned and produced in accordance with the ACCME Essentials.
Obtaining CME Credit:
This program is intended for psychiatrists and primary care physicians and will be available from May 26, 2003 until May 26, 2004. To receive your CME certificate, please fill out the activity evaluation and posttest on this website. The registration fee for this CME activity has been waived by the grantor.
Financial Sponsor:
We gratefully acknowledge an unrestricted educational grant from GlaxoSmithKline to help make this activity possible.
Privacy Statement:
MediMax Communications, Inc. maintains high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
The only information MediMax Communications, Inc. obtains about visitors to our website is information supplied voluntarily by the visitor. This means that you can visit our website without telling us who you are or revealing any information about yourself. Our Web server recognizes which pages people visit on our site; a visitor’s identity is not revealed.
Any personal information you may choose to provide to request information or to select services may be used the same way as information obtained off-line… for example, to evaluate service needs and contact you regarding our services.
We do not sell or disclose individually identifiable information obtained on-line unless it is required by law, or disclosure is necessary to protect the safety of customers, employees, or property. You may receive information from us regarding upcoming conferences in which you may be interested.
MediMax Communications, Inc. is committed to safeguarding customer privacy and we require our employees to protect the privacy of information about our customers. We employ security measures to safeguard your transactions with us. Should you wish to delete your information from our files or discuss our privacy policy, please contact us.
|
